Your browser doesn't support javascript.
loading
Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment.
Toplak, Zan; Hendrickx, Louise A; Abdelaziz, Reham; Shi, Xiaoyi; Peigneur, Steve; Tomasic, Tihomir; Tytgat, Jan; Peterlin-Masic, Lucija; Pardo, Luis A.
Afiliação
  • Toplak Z; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • Hendrickx LA; Department of Toxicology and Pharmacology, University of Leuven, Leuven, Belgium.
  • Abdelaziz R; AG Oncophysiology, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.
  • Shi X; AG Oncophysiology, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.
  • Peigneur S; Department of Toxicology and Pharmacology, University of Leuven, Leuven, Belgium.
  • Tomasic T; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • Tytgat J; Department of Toxicology and Pharmacology, University of Leuven, Leuven, Belgium.
  • Peterlin-Masic L; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • Pardo LA; AG Oncophysiology, Max-Planck Institute for Experimental Medicine, Göttingen, Germany.
Med Res Rev ; 42(1): 183-226, 2022 01.
Article em En | MEDLINE | ID: mdl-33945158
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canais de Potássio Éter-A-Go-Go / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canais de Potássio Éter-A-Go-Go / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article